A metabolite-based liquid biopsy for detection of ovarian cancer.
Biomarkers
Early detection
Metabolites
Ovarian cancer
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
received:
16
05
2024
accepted:
31
07
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
27
8
2024
Statut:
epublish
Résumé
Serial CA125 and second line transvaginal ultrasound (TVS) screening in the UKCTOCS indicated a shift towards detection of earlier stage ovarian cancer (OvCa), but did not yield a significant mortality reduction. There remains a need to establish additional biomarkers that can complement CA125 for even earlier and at a larger proportion of new cases. Using a cohort of plasma samples from 219 OvCa cases (59 stage I/II and 160 stage III/IV) and 409 female controls and a novel Sensitivity Maximization At A Given Specificity (SMAGS) method, we developed a blood-based metabolite-based test consisting of 7 metabolites together with CA125 for detection of OvCa. At a 98.5% specificity cutpoint, the metabolite test achieved sensitivity of 86.2% for detection of early-stage OvCa and was able to capture 64% of the cases with low CA125 levels (< 35 units/mL). In an independent test consisting of 65 early-stage OvCa cases and 141 female controls, the metabolite panel achieved sensitivity of 73.8% at a 91.4% specificity and captured 13 (44.8%) out of 29 early-stage cases with CA125 levels < 35 units/mL. The metabolite test has utility for ovarian cancer screening, capable of improving upon CA125 for detection of early-stage disease.
Identifiants
pubmed: 39192316
doi: 10.1186/s40364-024-00629-2
pii: 10.1186/s40364-024-00629-2
doi:
Types de publication
Letter
Langues
eng
Pagination
91Informations de copyright
© 2024. The Author(s).
Références
Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers. 2007;23(5–6):397–410.
doi: 10.1155/2007/309382
pubmed: 18057523
pmcid: 3851959
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
doi: 10.3322/caac.21387
pubmed: 28055103
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303.
doi: 10.1001/jama.2011.766
pubmed: 21642681
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182–93.
doi: 10.1016/S0140-6736(21)00731-5
pubmed: 33991479
pmcid: 8192829
Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, et al. A MYC-driven plasma polyamine signature for early detection of ovarian cancer. Cancers (Basel). 2021;13(4):913.
doi: 10.3390/cancers13040913
pubmed: 33671595
pmcid: 7927060
Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, et al. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clin Cancer Res. 2022;28(21):4669–76.
doi: 10.1158/1078-0432.CCR-22-1113
pubmed: 36037307
pmcid: 9633421
van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007;109(9):1887–96.
doi: 10.1002/cncr.22594
pubmed: 17373668
Engbersen MP, Van Driel W, Lambregts D, Lahaye M. The role of CT, PET-CT, and MRI in ovarian cancer. Br J Radiol. 2021;94(1125): 20210117.
doi: 10.1259/bjr.20210117
pubmed: 34415198
pmcid: 9327775
Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival - population cohort study in the “no screen” arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020;158(2):316–22.
doi: 10.1016/j.ygyno.2020.05.002
pubmed: 32561125
pmcid: 7453382
Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705–12.
doi: 10.1001/jama.291.22.2705
pubmed: 15187051
Walker M, Jacobson M, Sobel M. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ. 2019;191(32):E886–93.
doi: 10.1503/cmaj.190281
pubmed: 31405835
pmcid: 6690830
Young Han C, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, et al. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Br J Cancer. 2024;130:861–8.
doi: 10.1038/s41416-023-02560-z
pubmed: 38195887
pmcid: 10912308
Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, et al. Normal risk ovarian screening study: 21-year update. J Clin Oncol. 2024;42(10)Jco2300141.